Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Annals of the Rheumatic Diseases2015. [2]Ahsan T, Erum U, Khowaja D, Dahani A. Delayed conventional DMAR
来源:Holten K, Paulshus Sundlisater N, Lillegraven S, et al. Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. Ann Rheum Dis. 2022 Mar;81(3...
11. Tavakolpour, S, Alesaeidi, S. Darvishi, M. GhasemiAdl, M. Darabi-Monadi, S. Akhlaghdoust, M, et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019; 38 ...
They note that the use of DMARDs as first-line therapy is not recommended, but second-line therapy with DMARDs is common. For psoriatic arthritis, DMARDs are beneficial as a second-line therapy, they opine.GoodemoteEglin Air Force Base Family Medicine ResidencyPatricia...
Antirheumatic Therapy: Actions and Outcomes Maria E. Suarez-Almazor Part of the book series: Progress in Inflammation Research ((PIR)) 697 Accesses Abstract Medical advances in the past few years have opened an exciting era in the treatment of rheumatoid arthritis (RA). For the first time,...
Furst DE (1998) Clinical pharmacology of combination disease-controlling (DCART/ DMAD) therapy in rheumatoid arthritis. Z Rheumatol 57:20-24FURST DE: Clinical pharmacology of combi- nation disease-controlling (DCART/DMARD) therapy in rheumatoid arthritis. Z Rheumatol 1998; 57: 20-4....
patients should be maintained on therapy for a minimum of 3 months to properly assess their response to therapy. A lack of response at 3 months is suggestive that a change in therapy may be indicated. Several studies indicate that patients who stop therapy due to lack of effectiveness could ...
上发表了题为Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study(脐带间充质干细胞治疗类风湿性关节炎患者的疗效和安全性:一项前瞻性I/II期研究)的临床研究报告该报告指出,传统的抗炎、缓解病情的抗风湿药物对类风湿性关节炎...
Early Arthritis Clinic (EAC) and the treatment in the Rotterdam Early Arthritis Cohort (tREACH), a treat-to-target steered trial in which biological DMARDs were started when patients had inadequate response to triple DMARD-therapy (methotrexate, sulfasalazine, and hydroxychloroquine), for the study....
RA(rheumatoid arthritis):类风湿关节炎;CAR-T(chimeric antigen receptor T cells):嵌合抗原受体T细胞 1.1 细胞因子阻断剂 肿瘤坏死因子抑制剂(TNFi)是最早应用于RA治疗的bDMARDs,其疗效充分,种类丰富。根据作用机制分为可溶性TNF受体-免疫球蛋白Fc段(IgG1 Fc)融合蛋白(代表药物依那西普,为上市最早的一种TNFi)和...